Jiudian Pharmaceutical announced that its products ferrous succinate tablets and indobufen tablets have been tentatively selected for the 12th national centralized drug procurement. Ferrous succinate tablets were approved for market in September 2019, with 2025 sales revenue of 52.22 million yuan, accounting for 1.68% of the company's operating revenue in the same period. Indobufen tablets were approved for market in September 2024, with no sales in 2025 and the first quarter of 2026. In the first quarter of 2026, Jiudian Pharmaceutical achieved revenue of 595 million yuan and net profit attributable to the parent company of 56.74 million yuan.
Hunan Jiudian Pharmaceutical Co LtdProducts tentatively selected for national procurement, likely leading to price cuts and reduced revenue.